<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55507">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02118532</url>
  </required_header>
  <id_info>
    <org_study_id>IN.PACT SFA China</org_study_id>
    <nct_id>NCT02118532</nct_id>
  </id_info>
  <brief_title>The IN.PACT SFA Clinical Study for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery Using the IN.PACT Admiral™ Drug-Eluting Balloon in a Chinese Patient Population</brief_title>
  <official_title>The IN.PACT SFA Clinical Study for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery Using the IN.PACT Admiral™ Drug-Eluting Balloon in a Chinese Patient Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm that the IN.PACT Admiral is safe and effective for
      the interventional treatment of new and non-stented restenotic lesions in the superficial
      femoral artery (SFA) and proximal popliteal artery (PPA) in Chinese patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary effectiveness endpoint: Primary patency within 12 months post-index procedure</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary patency is defined as freedom from clinically-driven target lesion revascularization (TLR)1 and freedom from restenosis as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) ≤ 2.4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>30 days post-index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A composite of freedom from device- and procedure-related mortality, freedom from major target limb amputation and freedom from clinicallydriven TLR within 30-day post-index procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>MAE is defined as all-cause mortality, clinically-driven Target Vessel Revascularization (TVR), major target limb amputation or thrombosis at the target lesion site, through 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death of any cause</measure>
    <time_frame>30 days, 6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Death of any cause at 30 days, 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization</measure>
    <time_frame>30 days, 6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clinically-driven TLR at 30 days, 6 and 12 months TLR at 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization</measure>
    <time_frame>30 days, 6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clinically-driven TVR at 30 days, 6 and 12 months TVR at 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major target limb amputation</measure>
    <time_frame>30 days, 6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Major target limb amputation at 30 days, 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombosis at the target lesion site</measure>
    <time_frame>30 days, 6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Thrombosis at the target lesion site at 30 days, 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first clinically-driven Target Lesion Revascularization</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time to first clinically-driven TLR through 12 months post-index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary sustained clinical improvement</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary sustained clinical improvement</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duplex-defined binary restenosis (PSVR &gt; 2.4) of the target lesion</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Duplex-defined binary restenosis (PSVR &gt; 2.4) of the target lesion at 6 and 12 months post-index procedure, or at the time of reintervention prior to any pre-specified time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duplex-defined binary restenosis (PSVR &gt; 3.4) of the target lesion</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duplex-defined binary restenosis (PSVR &gt; 3.4) of the target lesion at 6 and 12 months post-index procedure, or at the time of reintervention prior to any pre-specified time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking capacity assessment</measure>
    <time_frame>30 days, 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Walking capacity assessment by Walking Impairment Questionnaire (WIQ) at 30 days, 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking distance</measure>
    <time_frame>30 days, 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Walking distance as assessed by 6 Minute Walk Test (6MWT) at 30 days, 6 and 12 months as change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>30 days, 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of life assessment by EQ5D questionnaire at 30 days, 6 and 12 months as change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>Post procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Device success is defined as successful delivery, balloon inflation, deflation and retrieval of the intact study device without burst below the rated burst pressure (RBP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>Post procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Procedural success is defined as residual stenosis of ≤ 50% (non-stented subjects) or ≤ 30% (stented subjects) by core lab assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success</measure>
    <time_frame>Post procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical success is defined as procedural success without procedural complications (death, major target limb amputation, thrombosis of the target lesion, or TVR) prior to discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of hospitalization due to the target lesion</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Days of hospitalization due to the target lesion from procedure through 6 and 12 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">143</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>IN.PACT Admiral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter</intervention_name>
    <description>IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter originally developed, approved and commercialized by Invatec Technology Center GmbH is the investigational medical device used in the study. Medtronic Inc. acquired Invatec on April 21, 2010. Medtronic</description>
    <arm_group_label>IN.PACT Admiral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years and ≤ 85 years.

          -  Subject with documented diagnosis of peripheral arterial disease (PAD) classified as
             Rutherford class 2-3-4 in the superficial femoral artery (SFA) and/or proximal
             popliteal artery (PPA) above the knee, located in the arterial segment starting at
             least 1 cm beyond the Common femoral artery (CFA) bifurcation between the superficial
             and profunda femoris arteries (proximal anatomical landmark to the distal P1 segment
             of the popliteal artery at the level of the proximal edge of the patella (distal
             anatomical landmark).

          -  Target lesion consists of a single de novo or non-stented restenotic lesion (or a
             tandem lesion) or is a combination lesion

          -  Reference vessel diameter ≥ 4 mm and ≤ 7 mm by visual estimate.

          -  Subject able to walk without assistive devices (e.g. walker, cane).

          -  If subject has ipsilateral/contralateral iliac disease that requires treatment during
             the index procedure

          -  Angiographic evidence of adequate distal run-off to the foot (at least one native
             calf vessel [posterior tibial, anterior tibial, or peroneal arteries] is patent,
             defined as &lt; 50% diameter stenosis).

          -  Female subjects of childbearing potential must have a negative pregnancy test ≤ 7
             days before index procedure and willing to use a reliable method of birth control for
             the duration of the study or must have documented adequate birth control.

          -  Signed and dated Patient Informed Consent (PIC) form.

          -  Understands and accepts the duration of the study and is able and willing to comply
             with all requirements, including follow-up visits and evaluations.

          -  Life expectancy, in the Investigator's opinion, of at least 12 months.

        Exclusion Criteria:

          -  In the investigator's opinion subject is unlikely to comply with the followup
             schedule.

          -  Stroke or STEMI within the 3 months prior to index procedure.

          -  Either local or systemic thrombolytic therapy within 48 hours prior to the index
             procedure.

          -  Inability to tolerate oral anticoagulation therapy (blood thinners such as warfarin)
             while on concomitant dual antiplatelet therapy (DAPT).

          -  Known allergies or sensitivities to heparin, aspirin (ASA), other
             anticoagulant/anti-platelet therapies, and/or paclitaxel or an allergy to contrast
             media that cannot be adequately pre-treated prior to the index procedure.

          -  Breastfeeding woman.

          -  Chronic renal insufficiency with serum creatinine &gt; 2.5 mg/dL within 14 days prior to
             index procedure.

          -  WBC &lt; 3.0 (3,000 cells/mm3) within 14 days prior to index procedure.

          -  PLT count &lt; 80,000 cells/mm3 or &gt; 700,000 cells/mm3 within 14 days prior to index
             procedure.

          -  Known or suspected active systemic infection evidenced by WBC &gt; 14.0 (14000/mm3)
             within 14 days prior to index procedure.

          -  Diagnosed with bleeding diatheses or hypercoagulable state.

          -  Subject is enrolled in another investigational device, drug or biologic study or
             subject was previously enrolled to the IN.PACT SFA China trial.

          -  Any major (e.g., cardiac. peripheral, abdominal) surgical procedure or intervention
             performed within 30 days prior to the index procedure.

          -  Any major (e.g., cardiac. peripheral, abdominal) elective procedure or intervention
             within 30 days post index procedure.

          -  Contralateral SFA/PPA disease requiring treatment in the same setting as index
             procedure.

          -  Presence of additional lesions in the target vessel that require treatment during
             index procedure but do not meet the definitions of tandem lesions.

          -  Target lesion is an in-stent or post-DEB restenosis or has been previously treated
             with bypass surgery.

          -  Failure to successfully cross the target lesion with a guide wire

          -  Lesion within or adjacent to an aneurysm.

          -  Acute or sub-acute thrombus in the target vessel.

          -  Angiographic evidence of severe calcification

          -  Target lesion known in advance of enrollment to require treatment with alternative
             therapy such as drug-eluting stent (DES), drug-eluting balloon (DEB), laser,
             atherectomy, cryoplasty, re-entry devices, cutting/scoring balloon, brachytherapy.
             Use of embolic protection devices is also prohibited.

          -  Pre-dilation resulted in a major ( ≥ Grade D) flow-limiting dissection (observed on 2
             orthogonal views) or residual stenosis &gt; 70% and translesional peak gradient &gt; 10mm
             Hg.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhong Chen, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vascular Department Anzhen Hospital, Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wei Guo, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vascular Department 301 Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefani Deckers</last_name>
    <phone>+31433566637</phone>
    <email>stefanie.deckers@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stijn Bollen</last_name>
    <phone>+3143366792</phone>
    <email>stijn.bollen@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhong Chen, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Zhong Chen, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>301 Hospital/Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Guo, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Wei Guo, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yongquan Gu, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Yongquan Gu, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Changwei Liu, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Changwei Liu, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yinghua Zou, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Yinghua Zou, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Feng Wang, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Feng Wang, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pingfan Guo, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Pingfan Guo, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The 1stAffiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guangqi Chang, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Guangqi Chang, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The 2nd Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weiliang Jiang, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Weiliang Jiang, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Changjian Liu, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Changjian Liu, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weiguo Fu, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Weiguo Fu, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zaiping Jing, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Zaiping Jing, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>April 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Superficial Femoral Artery</keyword>
  <keyword>Proximal Popliteal Artery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
